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Abstract 
Granulocyte Colony Stimulating Factor (G-CSF) is a hematopoietic growth factor that 
controls the proliferation, differentiation and the function of neutrophils. G-CSF is 
clinically used in human for the treatment of neutropenia in diseases such as AIDS, 
aplastic anaemia, myelodysplastic syndrome, and congenital or chemotherapy-induced 
neutropenia. However, the bioactivity and stability of commercially available 
recombinant hG-CSF such as Filgrastim and Lenograstim are lower than endogenous G-
CSF. The objective of the present study is to express recombinant hG-CSF in E.coli along 
with SCF as a fusion partner to improve the bioactivity. In the present study, in silico 
analyses were performed for finding the possible mutant variants of G-CSF which may 
increase the stability of the recombinant hG-CSF for its incorporation into hG-CSF by 
site-directed mutagenesis and also analyse the binding affinity of the G-CSF-SCF fusion 
protein with G-CSF receptor (G-CSF-R) and SCF receptor (SCF-R). A total of 5 mutant 
variants of hG-CSF was generated and docked with GCSF-R using Hex dock 8.0 
software. In order to analyse the binding affinity of the G-CSF-SCF fusion protein, 
docking analyses of the fusion protein with GCSF-R and SCF-R were performed using 
patch dock server. Human G-CSF gene (547 bp) was isolated from human Umbilical 
Cord Blood and U-87 cell line. The hG-CSF gene was cloned into TOPO-TA vector for 
sequencing followed by cloning into the pET14b vector for expression using Nde I and 
Bam HI restriction ends. Human GCSF gene was then end modified to fuse with the 
fusion partner. Besides, Human SCF gene (567 bp) was purchased from GenScript™ in 
the pUC57 cloning vector. It was restriction digested from the pUC57 vector using Bam 
HI and Xho I restriction enzymes. The restriction digested hG-CSF, SCF inserts were 
inserted into pET14b vector containing Nde I and Xho I restriction ends. The ligated 
expression vectors were then transformed into chemically competent DH5α cells followed 
by plasmid extraction and transformation into expression host E.coli BL21 (DE3).The 
expression of human G-CSF and G-CSF-SCF protein in E.coli was confirmed using SDS-
PAGE analysis. Further expression profile of the proteins was optimised to increase the 
protein expression. From the in silico analysis, it was found that the mutant variant 5 may 
have improved biostability than the wild type G-CSF variant. The study was also found 
that the G-CSF-SCF fusion protein has high binding affinity to G-CSF-R and SCF-R from 
 v 
 
the global energy values. Furthermore, increased level of G-CSF and G-CSF-SCF fusion 
protein observed under optimised IPTG concentration of 1mM, post-induction duration of 
8h and at 3% of ethanol concentration. 
Key words: G-CSF, SCF, Fusion protein, In silico analysis, BL21DE3, cloning, 
transformation, expression, optimization. 
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Chapter 1 
Introduction 
  
Therapeutic proteins are produced from their native source in a very small amount and so 
for its use in the pharmaceutical market necessitates a large scale production.  The 
principles of genetic engineering can be therefore use for the production of recombinant 
proteins to meet the market demand. Large scale production of recombinant proteins for 
their application in the field of biotechnology and medicine includes cloning a gene of 
interest in a desired expression vector under the control of an inducible promoter and 
subsequent expression of it. The first expression platform of recombinant therapeutic 
proteins was the Escherichia coli system. E. coli is a well-established host that offers easy 
genetic manipulation, short culturing time, and low cost. Furthermore, Engineered E. coli 
strains has   ability to produce a wide variety of different types of proteins includes 
protein containing disulfide bonds. With a large knowledge on the molecular genetics, 
simple cultivation requirements such as growth on inexpensive carbon sources, rapid 
biomass accumulation and a short generation time E. coli remains the first choice as an 
expression host [12]. 
 
Colony Stimulating Factors (CSF) are the group of cytokines involving in the 
hematopoiesis process formation in which a small number of self-renewing stem cells 
proliferate and differentiate into mature blood cells. Different CSFs act on bone marrow 
cells to generate different lineages of hematopoietic cells. Granulocyte colony stimulating 
factor (G-CSF) is a hematopoietic growth factor that stimulates the proliferation, 
differentiation and the function of neutrophils. Cancer patients receiving chemotherapy 
are vulnerable to potentially life-threatening infections due to suppression of white blood 
cells production. G-CSF thus has been permitted for the treatment of neutropenia in 
cancer patients, a condition which appears after chemotherapy. Furthermore, G-CSF also 
has neuroprotective properties which have been used as a protective agent in a variety of 
neurodegenerative diseases. 
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Human granulocyte colony-stimulating factor (G-CSF) is an 18.8 kDa protein. 
Alternative splicing of G-CSF mRNA encodes two transcript variants of 207 and 204 
amino acid residues respectively. The initial 30 amino acid residues at N-terminal region, 
responsible for secreting the mature protein outside the cell. The insertion or deletion of 3 
amino acid residues around the 35th amino acid residue is responsible for the difference 
between two transcript variants of G-CSF.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Crystal structure of recombinant human G-CSF.  
 
Transcript variant 2 with 174 amino acid residues is found to be 20 times more active 
than the transcript variant 1 with 177 amino acids. The nucleotide sequence of G-CSF 
contains two intramolecular disulphide bonds between Cys36-Cys42 and Cys64-Cys74 
and a cysteine at residue 17. Furthermore, O-glycosylation site at Thr133 in G-CSF is not 
essential for biological activity. Accordingly, the biological activity of nonglycosylated 
recombinant hG-CSF is as same as glycosylated hG-CSF. So the G-CSF can be 
effectively produce using prokaryotic protein expression system. 
The hematopoietic system is a hierarchical structure in which non-replicative mature 
blood cells are synthesized by multipotent stem cells. Several hematopoietic growth 
factors play a major role in hematopoiesis. Some growth factors (e.g., GMCSF) have a 
broad array of effect on very early hematopoietic progenitors, leading to multilineage 
increases in hematopoietic cell differentiation, while others (e.g., G-CSF) appear to act 
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mainly on more terminally differentiated cell types, producing moderately profound 
changes in specifically committed populations, such as neutrophils. 
Hematopoietic growth factors have redundant properties. Redundancy is defined as the 
production of the same effect by different factors. In addition, the factors are pleiotropic, 
implying that different effects can be mediated by one cytokine. Some cytokines such as 
GMCSF, SCF, IL-3, IL-6, and IL-1 1 have been proved to stimulate granulopoiesis with 
efficiencies less than that of G-CSF. But it has also been shown that if those cytokines act 
synergistically with G-CSF, maximum granulopoiesis can be attained. One way to 
increase the effect of G-CSF in granulopoiesis is the combined administration of G-CSF 
with other hematopoietic growth factors. Several finding indicates that G-CSF exert it 
activities by acting synergistically and sequentially with other cytokines mainly GMCSF, 
SCF, IL-3 which raises the potential application of G-CSF fusion proteins. Stem Cell 
Factor is one of the cytokines that plays a major role in hemetopoiesis, melanogenesis and 
spermatogenesis. If the synergistic effect occurs between G-CSF and SCF, fusing both of 
them will increase the bioactivity of the growth factor.  
 
 
 
 
 
 
 
 
 
 
Figure 2: The effect of multiple hematopoietic growth factors in the production of neutrophil and 
megakaryocytes [35] 
 
E.coli T7 expression system is the most reliable and successful system for the production 
of heterologous proteins like Insulin and human growth hormone. In T7 expression 
system, a gene of interest is cloned downstream to the T7 promoter of the expression 
vector which is then transformed into T7 expression host. T7 expression hosts carry the 
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phage T7 polymerase gene which upon the addition of inducer results in the transcription 
of the inserted gene of interest. Also high density culture achieved with simple process 
scale up makes the culture process economical and so this platform has been used for 
successful production of recombinant proteins like insulin and human growth hormone. 
The pET vector System is the most effective system for the expression and cloning of 
recombinant proteins in E. coli. pET vector system has been the potent choice for the 
expression of proteins that have been difficult to produce using E. coli promoter-based 
systems such as  tac, pL, lac, have been successfully cloned and expressed stably in the 
pET System. Target gene expression in pET plasmids is induced by T7 RNA polymerase 
of the host cell. Apart from the bacteriophage-based promoter, pET vectors also carry 
several of the fusion tags at the 5' end. Besides, pET vectors also contain protease 
cleavage sites such as thrombin, enterokinase that provides selective removal of tags 
following purification.  
 
Figure 3: Control Elements in pET Vector System 
 
E. coli BL21 (DE3) is an ideal strain for the T7 promoter based expression systems like 
pET and , pRSET . BL21DE3 contains the lambda DE3 lysogen. DE3 expresses T7 RNA 
polymerase from the lacUV5 promoter to allow simple induction of recombinant proteins 
with IPTG. Expression of non-toxic recombinant proteins in E. coli is higher in BL21 
(DE3) cells than in BL21 (DE3) pLysE or BL21 (DE3) pLysS. 
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Figure 4: BL21DE3 strain 
 
 But the basal level expression of heterologous genes are considerably higher in BL21 
(DE3) pLysS or BL21 (DE3) pLysE. However, a shortcoming associated with the use of 
E. coli system is the inability to synthesize recombinant proteins with post translational 
modification cells (e.g., human, Chinese hamster Ovary) has been successfully used as 
expression systems. 
In silico analysis of the interaction of wild and mutated proteins with the G-CSF receptor 
and SCF receptor can give us an inference of how the wild and mutants are interacting 
with the receptor by calculating the binding energy values. Negative energy values predict 
better interaction of the ligand and receptor. Protein modelling software can be used for 
modelling the mutant proteins which can be then docked with the receptor using a 
docking software. Mutations created can change the stability of the protein. So to evaluate 
the change in stability upon mutation various protein stability determining software can 
be used. For achieving maximum production of a product the process condition for 
growth of the bacteria must be optimized. 
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Chapter 2 
Literature Review 
 
Impressive advancement in recombinant DNA technology in the past decades has 
produced several therapeutic proteins for clinical application. Scientists are intended to 
better the technology to speed up the clinical trial process as there are thousands of 
therapeutic proteins are lined up for the approval. [13]. One of the major hurdles in the 
application of therapeutic proteins in clinical applications is the reduced half-life and 
activity of the therapeutic protein compared to its wild type counterparts. Expression 
system employing gene fusion constructs is the possible solution to increase the 
bioactivity and stability of the therapeutic protein. The advent of synthetic biology also 
made it possible to express chimeric fusion proteins to increase the overall bio activity of 
the therapeutic protein. One of the greatest outcomes of expressing fusion protein remains 
in the field of biopharming. Biopharming is the production of physiologically important 
therapeutic proteins through genetically engineered plants and animals [29] in high 
volume. 
2.1 Human granulocyte colony stimulating factor 
Human granulocyte colony-stimulating factor (hG-CSF) is a hematopoietic growth factor 
involves in controlling differentiation, proliferation, and efficient activation of blood cells 
[48]. It is an important growth factor for neutrophil proliferation both in vivo and in vitro. 
Large quantities of recombinant human G-CSF are produced using genetic engineering 
and it is successfully used to neutropenia condition in cancer patients which appear after 
chemotherapy. 
2.1.1 The structure of G-CSF 
The native hG-CSF is an 18.9 kilo Dalton glycoprotein consisting of 174 amino acid 
residues. It has O-linked carbohydrate group linked to Thr 133 [38, 39, 40]. The X-ray 
crystallography studies have revealed that the three-dimensional structure of G-CSF 
contains four antiparallel alpha helical structures with the left-handed twist [5]. The four 
helices are represented as helices A-D. The loops linking the helices are showed as AB, 
BC, and CD (Figure 5). Human G-CSF contains two disulphide bonds at positions Cys36-
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Cys42 and Cys64-Cys74.Human G-CSF contains two disulphide bond at positions 
Cys36-Cys42 and Cys64-Cys74. 
 
 
Figure 5: Native structure of hG-CSF protein [27] 
 
G-CSF shares four alpha helix bundle with two long crossover connection structure with 
GMCSF, GH, IFN- α, IL-2, and IL-4. Although hG-CSF is an important protein not only 
for basic science but also for therapeutic use, the detailed activation mechanism of hG-
CSF-R has not been clarified till yet [46]. Moreover, study of the crystal structure has 
revealed the atoms involved in the molecular positioning and recognition for the 2:2 
complex; there is ligand-receptor interaction at two locations (site II and III). Thus, 
homodimerization of receptors by this 2:2 complex is elucidated to be an important 
feature for hG-CSF-R activation. 
 
 
Figure 6: G-CSF and G-CSF Receptor interaction. A: Homo-dimerization B: G-CSF-R activation 
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2.1.2 The genetics of G-CSF 
Gene for human G-CSF is present in the long arm of chromosome 17. G-CSF gene 
contains 5 exons and 4 interrupting introns. Primary G-CSF transcripts give two different 
transcript variants upon splicing. As shown in the figure 7, two sequences for alternative 
splicing are organized in tandtem  at the 5' end of intron 2. Transcript variant 1 is formed 
by splicing at 380/381 position whereas transcript variant 2 produced by splicing at 
371/372 position. The second donor sequence [38]. More than 80% of hG-CSF mRNA 
produced belongs to transcript variant 2 type. 
 
 
Figure 7: Alternative splicing of G-CSF mRNA [38] 
 
2.1.3 The functions of G-CSF 
Due to increased occurrences of bone disorders, the need for bone grafts is increasing 
corresponding to the demand. But, the availability of the autografts and allografts depends 
on the various factors which cannot be controlled. After several years of research still, the 
autograft serves as the gold standard as it does not face Graft rejection from the host's 
body, the biggest disadvantages are double surgery and highly expensive. Allografts are 
highly histocompatible they can also be used after decellularization of bone matrix, bone 
chips etc.[10]. The various other strategies adopted to repair the bone disorders or 
fractures include bone cement and involvement of bone morphogenetic proteins. The 
bone graft designed in vitro should be osteoinductive as well as angiogenic in nature to 
support the regeneration of the bone on the site of implantation. This leads to the 
necessity to develop the Bone grafts in vitro for implantation into the patients.  
2.1.4 Clinical Importance of G-CSF 
The role of G-CSF to infection associated with bacterial pathogens like Listeria 
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monocytogenes, Pseudomonas aeruginosa and Candida albicans has been elucidated by 
various researchers. L. monocytogenes causes infection by propagating within the 
macrophages and the important role of G-CSF in suppressing bacterial load by promoting 
phagocytosis has been well studied in vivo using G-CSF deficient mice models. G-CSF 
plays a major role in bacterial clearance by controlling macrophage responses and 
circulating neutrophil levels. 
2.2 Hematopoietic growth factors 
The significance importance of the bone marrow microenvironment relies mainly on the 
production of hematopoietic growth factors that are important for the proliferation, 
differentiation and eventual function of monocyte, granulocyte, basophils and 
eosinophils. Erythropoietin, produced by the interstitial cells in kidney, is responsible for 
the production of RBC. 
 
Figure 8: Hematopoietic Growth Factors [50] 
 
Furthermore, early acting growth factors such as GMCSF, SCF, flt3 support initial growth 
of hematopoietic cell line. Furthermore, GMCSF also stimulates the phagocytic and 
cytotoxic activity of monocyte and granulocyte. G-CSF, on the other hand, stimulates the 
functional characteristic of granulocytes. MCSF increases the functional activity of 
monocytes. Sequential and synergistic interaction of different growth factors is important 
for the differentiation of hematopoietic cell line. It has been reported that the in vivo 
combination of EPO, G-CSF, GMCSF, SCF and IL-11. The in vivo effects of a combined 
administration and all possible combinations of erythropoietin (EPO), G-CSF, interleukin 
1 (IL-11), and stem cell factor (SCF) have been studied and reported by modifying the 
quantitative and qualitative dose response characteristics of the cytokines [50]. 
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2.3 G-CSF fusion protein 
Several methods have been used to enhance the half-life of drugs. Increasing the half-life 
of protein and peptide drugs by protein fusion technology is one of the most widely used 
methods in molecular biology practices. Based on the development of molecular biology 
and genetic engineering, some natural proteins with long half-life have been used as 
fusion partners to enhance the circulating half-life of drugs, such as IgG-Fc, transferring 
(tf), and human serum albumin (HSA). HSA-G-CSF fusion protein has been studied and 
reported that it has longer half-life than the native G-CSF protein [53]. The G-CSF-tf 
fusion protein has also been reported to increase the absolute neutrophil count upon oral 
administration than the 3 native G-CSF [7]. The bacterial stress responsive proteins such 
as bacterioferritin (Bfr), chemotaxis protein cheZ (CheZ), HTH-type transcripttional 
regulator yjdC (YjdC), HTH-type transcripttional regulator yjdC (YjdC), HTH-type 
transcripttional regulator yjdC (YjdC), peptidyl-prolyl cis–trans isomerase B (PpiB), and 
glutathione synthetase (GshB) have been used as a fusion expression partner with G-CSF 
and reported that these stress responsive proteins act as a folding enhancer. Similarly, 
high yield and high solubility of G-CSF protein have been reported by combining Maltose 
Binding Protein (MBP) and Protein Disulphide Isomerases (PDI) with G-CSF [21]. G-
CSF/SCF fusion protein with higher biological activity than native G-CSF has been also 
patented (WO2015047062 A1, 2013) The present study aims to produce fusion protein of 
G-CSF with hematopoietic growth factor such as IL-3, GMCSF and SCF and to increase 
the biological activity of the protein. 
2.4 Stem Cell Factor (SCF) 
Stem Cell Factor is a co stimulatory Hematopoietic Growth Factor plays a major role in 
proliferation and differentiation of the early hematopoietic stem cells. SCF, when 
combine with cytokines such as G-CSF, GMCSF, IL-3, TPO, EPO, resulting in a 
synergistic improvement of the development and survival of hematopoietic cells. On 
marrow cells in semi-solid culture, SCF shows pronounced synergy with factors such as 
IL-6, IL-1, IL-3, IL-7, granulocyte CSF, granulocyte-macrophage CSF, and 
erythropoietin [2, 26,33, 54, 55]. The colonies generated are larger and more numerous 
than those with the latter factors individually. Apart from Hematopoiesis, SCF also have 
an important role in melanogenesis and spermatogenesis. The therapeutic applications of 
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SCF consist of hematopoietic stem cell (HSC) mobilization, gene therapy, 
immunotherapy and ex vivo stem/progenitor cell expansion. It appears that SCF enhances 
the proliferation and differentiation of progenitors in these cultures but that lineage 
commitment is controlled by the later-acting factor [4]. 
2.4.1 Biology of Stem Cell Factor 
In human, gene code for SCF protein is present at the long arm of chromosome no 12 
whereas in mouse, it is located at the SI locus of the chromosome [2, 6, 26, 54, 55].  
Alternative splicing of SCF results in the soluble and transmembrane forms of SCF that 
either includes or excludes a proteolytic cleavage site [11]. The proteolytic cleavage 
occurs after Ala 165. The transmembrane form of SCF (SCF 220)   lacks exon 6 in which 
amino acids 149-177 are substituted by a Gly residue. In its native state, SCF exists as a 
monomer. SCF undergoes spontaneous dissociation–reassociation of monomers to form 
the non-covalent SCF homodimer. The specific activity of SCF dimers are 10–20 times 
higher than the specific activity of the monomer. On purified human progenitor stem cell 
populations in vitro, it has a unique maintenance-enhancing capability and when given in 
combination with other cytokines, such as granulocyte CSF, granulocyte-macrophage 
CSF, IL-6, IL-3, and erythropoietin, there is marked proliferation which is not seen with 
the other factors given alone or in combinations (WO2015047062 A1). 
2.5 Synergistic effect of G-CSF and SCF 
Hematopoietic cell maturation and function depends on the action of several cytokines 
and growth factors. These growth factors modulate the differentiation of the progenitor 
cells and controls the final stage cell functions. Synergistic effect of SCF with G-CSF 
plays a significance role in hematopoiesis. SCF and G-CSF are important growth factors 
for the growth of human primitive hematopoietic cells in vitro [10]. In addition, the 
increased mobilization of blood progenitor cells (PBPC) was found to be higher with the 
combination of SCF and G-CSF in vivo than that was with G-CSF alone [3, 10, 18]. 
Furthermore, several studies have reported that the SCF and G-CSF combination 
increases the CD34 cells counts in patients at risk of poor PBPC mobilization [22, 37, 
44]. 
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Figure 9: Integration of SCF and G-CSF signaling pathways [21]. 
 
Signaling pathways of G-CSF and SCF upon binding with its respective receptors, unite 
on STAT-3signal transduction, which become phosphorylated on serine and tyrosine 
residues, and carry out the consequent biological effects such as MAPK, Jak–STAT and 
PI3K signaling pathways [21]. 
2.6 Recombinant forms of G-CSF 
Similar to the other colony stimulating factors, G-CSF is also present in small quantity in 
our system similarly. The quantity of CSFs has been reported as low in macrophages, 
fibroblasts, monocytes, endothelial cells, and bone marrow cells [34]. In order to use G-
CSF as a drug, the gene of G-CSF was cloned and expressed as a recombinant protein 
[42], [43]. Currently, recombinant hG-CSF (rhG-CSF) is a recognized commercially 
available recombinant protein, has been used mainly for neutropenias. There are several 
forms of recombinant G-CSF is currently available such as filgrastim, neupogen, 
nartograstim and pegfilgrastim. Opti-nartogratimhas been successfully produced and 
reported as a codon optimized form of (for bacterial expression system) nartograstim 
which shows similar biological activity as native G-CSF [32]. In this present study we are 
trying to produce the G-CSF fusion protein in BL21DE3 host. Filgrastim, a recombinant 
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form of G-CSF is commercially being used as a drug to treat neutropenia condition after 
chemotherapy, and in patients undergoing bone marrow transplantation. Filgrastim a non-
glycosylated recombinant human G-CSF has a methionine group at its N-terminal end 
[43].  Lenograstim a glycosylated recombinant human G-CSF) is produced using Chinese 
Hamster Ovary cells with 4 % glycosylation. Pegfilgrastim is the non-glycosylated human 
G-CSF with PEG moiety to mask the proteolytic cleavage sites and reduces the renal 
excretion of the protein thereby elevating the serum level of G-CSF [43]. Nartograstim, a 
mutant variation has also been expressed in E. coli with mutations at N-terminus and a 
substitution of cysteine at its 17
th
 position [25].  
2.6 Engineering human G-CSF for improved bioactivity 
Various recombinant preparations of human G-CSF has been engineered with enhanced 
biological activity and physiochemical properties. Site directed mutagenesis, a protein 
engineering tool has been used for modification of specific sites in a nucleotide sequence 
for production of mutants. The simplest and most widely used approach in this regard is 
the Quick Change Site-Directed Mutagenesis System developed by Stratagene. Using this 
approach, desired mutations can be introduced using a thermal cycler and with a pair of 
complementary primers containing the desired mutation. G-CSF has one free cysteine at 
its 17
th
 aminoacid position and has two disulfide bridges (Cys36-Cys42 and Cys64-
Cys74). It has been reported in various literatures that free cysteine molecules are 
involved in intermolecular thiol/disulfide interchange that leads to formation of inactive 
oligomers. The Cysl7 was substituted with aminoacids like Gly, Ser, Tyr, Arg, Ala, He, 
and Pro, or was deleted using site-directed mutagenesis in order to study the effect on 
thermo stability and bioactivity of the protein. The results obtained inferred that the 
replacement of Cysl7 with Ala improved the heat-stability of mutated protein by five 
times than the wild type [28]. KW-2228(Neu-up) is a modified human granulocyte 
colony-stimulating factor in market with enhanced bioactivity and stability and is known 
to possess more granulopoiesis activity than the wild-type human G-CSF. In the wild type 
G-CSF Cys
17 
is situated in the core surrounded by hydrophobic residues. When Cys
17 
was 
substituted with Ser, hydrogen bond was formed in between hydroxyl group of Ser and 
carbonyl group of Leu
14 
that eventually lead to the stability of the protein. Similar results 
were obtained for all other N terminal mutations [24]. Amino acid residues in the G-CSF 
receptor binding interface has been mutated to construct rHSA/G-CSF mutants. Mutant 
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G-CSF fusion protein is a fusion protein that stimulates the proliferation of neutrophilic 
granulocytes, and has a basic structure of G-CSF conjugated with carrier protein or carrier 
protein with G-CSF, in which the G-CSF has one of the K34H, L35I, K40H, and L41I 
substitutions or its combinations [51]. The mutants designed were expressed in Pichia 
pastoris and for the obtained mutants, the ligand-receptor affinity was determined by 
using surface plasma resonance (SPR) technology. Through the SPR technology an 
association rate constant and a disassociation rate constant was obtained, and a ligand-
receptor equilibrium disassociation constant was determined. The larger the equilibrium 
disassociation constant the lower is the ligand-receptor affinity. When rHSA/G-CSF was 
compared with rHSA/G-CSF mutants it was found that the substitution in the sites of 
K34H, L35I, K40H, and L41I gave higher equilibrium disassociation constant. So 
compared with rHSA/G-CSF, the mutants designed had a longer half-life, lower binding 
affinity and an improved biological activity [51]. Variant forms of G-CSF have been 
designed with substitution of Leu in place of Met elucidating increased stability against 
oxidation [31]. 
G-CSF has been successfully engineered for enhancing the thermodynamic stability 
without interfering with the receptor binding sites. An unusual abundance of glycine 
residues is found in the helices of G-CSF that results in low intrinsic alpha-helical 
propensity [9]. Glycine to alanine substitutions is expected to increase protein stability. 
After experimental replacement of glycine residues with amino acid alanine at specific 
positions 26, 28, 149, and 150 resulted in high increase in the stability of protein. Also 
after evaluating first generation mutant, second and third generation mutants were also 
designed and studied for increased stability over wild type G-CSF. Second and third 
generation Gly/Ala substitutions which elucidated that with an increase in intrinsic alpha-
helix propensities increased the overall protein stability [9]. 
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Chapter 3  
Objectives  
3.1 Objectives 
The major objective of this study was to express recombinant hG-CSF in E.coli 
expression vector system along with SCF as fusion partner to improve the bioactivity. 
The specific Objectives are, 
1. To isolate and clone human G-CSF and SCF. 
2. To construct expression vector for expression of G-CSF and SCF 
3. To co-express hG-CSF and hSCF as a fusion partner 
4. To optimize bioprocess parameter for expression of hG-CSF. 
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Chapter 4 
Material and Methods 
 
All materials were purchased from HiMedia Lab (Mumbai, India) unless otherwise 
specifically indicated. 
Total RNA was extracted from discarded Umbilical Cord matrix and/or blood by 
informed consent from IGH, Rourkela and U-87 human glioblastoma cells and hG-CSF 
(CSF3) was PCR amplified. The hG-CSF cDNA was obtained by extracting the total 
RNA from Umbilical Cord Blood followed by 2 step RT-PCR. The primers were 
designed accordingly for both verification and cloning. 
4.1 Preparation of Blood Cell Pellet for Extracting RNA 
The blood was collected in appropriate Haemobag with heparin and antibiotics and was 
stored at mentioned temperature (4°C). The blood was transferred to 15 ml centrifuge 
tube with proper sterilization procedure. For 1ml of blood,3 ml of 1X of RBC lysis buffer 
was added. The contents were mixed properly by inverting the tubes and was allowed to 
stand at RT for 10min. The cells were centrifuged at 600xg for 10 minutes at RT to obtain 
cell pellet. The supernatant after centrifugation was decanted and the pellet obtained was 
gently resuspended in 1 ml of 1X RBC lysis buffer and was allowed to stand for 5 
minutes at RT. The cells were pelleted for 2 minutes by centrifuging at RT at 3000 rpm. 
The supernatant was decanted and the pellet was carefully resuspended in 1 ml of sterile 
1X DPBS. The obtained cells were pelleted at 3000rpm for 2 minutes at RT and the 
collected pellet was used for RNA extraction. 
4.2 Total RNA Extraction Protocol: RNA-XPress
TM
 Reagent 
The cell pellet (50-100mg) was transferred to a clean nuclease free epi Tube. About 1ml 
of RNA Xpress Reagent was added per 50-100 mg of tissue/pellet. Homogenized & 
Incubated for 5 mins @ RT. Centrifugation was done at 12000g at 4°C for 10 minutes. 
The obtained supernatant was collected in a sterile centrifuge tube (this step was for 
avoiding fat and lipid bilayer mixing with the aqueous phase).200μL of chloroform 
(Himedia MB109) was added to it and shaken vigorously for 15 sec. The tubes were then 
incubated at room temperature for 10 minutes. Centrifugation was carried out at 12000g 
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for 15 minutes at a temperature of 4°C. The obtained supernatant was collected in a sterile 
centrifuge tube. About 500μL of isopropyl alcohol (Himedia MB063) was added. The 
tubes were inverted few times to mix briefly and were incubated for 10 min at RT. 
Centrifugation was done at 12000g at at 4°C for 10 minutes and supernatant was 
completely removed by inverting the tube upside down. 1mL of 75% ethanol (Himedia 
MB106) (MB Grade, in DEPC water) was added. Centrifugation was carried out at 7500 
g at 4°C for 5 minutes and the pellet was allowed to air dry. The pellet was finally 
resuspended in nuclease free water (~50μL) and was allowed to dissolve by heating for 10 
min at 55-60°C. The dissolved RNA was processed immediately. 
4.3 First strand cDNA synthesis 
 Complementary DNA was synthesized using the High-Capacity cDNA Reverse 
Transcription Kit (Applied BiosystemsTM – 4368814) in a Veriti® 96 well thermal 
cyclers (Applied Biosystems) using the manufacturer’s cycle conditions with 
modifications and random primers(supplied) as mentioned in the product protocol. The 
synthesized cDNA was then verified for genomic DNA contamination using the gene 
specific exon-exon boundary primers followed by agarose gel electrophoresis. The cDNA 
was then stored at -20°C. The cDNA reaction composition is given in table 1 and the PCR 
conditions are given in table 2. 
 
Table 1:cDNA reaction composition 
Initial Conc Sample Volume for 1 reaction(µl) 
10X RT buffer 2.0 
25X DNTPs 0.8 
10X Random primer 2.0 
 RNA 10.0 
 Reverse Transcriptase 1.0 
 Nuclease Free water 4.2 
 Total volume 20 
   
Table 2: cDNA Synthesis Conditions 
Step 1 Step 2 Step 3 Step 4 
 
25 ̊C 37 ̊C 84 ̊C 4 ̊C 
10 min 120 min 5min ∞ 
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4.4 Polymerase Chain Reaction for amplification of human G-CSF  
PCR was carried out to amplify the hG-CSF gene from DNA extracted from U-87 cell 
line and human umbilical cord blood using specific primer pairs and AmpliTaq Gold 
360® Master Mix (Applied Biosystems – 4398881) in a Veriti® 96 well thermal cyclers 
(Applied Biosystems). The primer was synthesized using Primer 3 software, Genome 
Compiler and was validated using Net Primer. The specificity of the primer pairs was 
tested using BLASTn. The primer synthesizing was outsourced from Bioserve, 
Hyderabad. The PCR cycle conditions and parameters used for an amplifying specific set 
of genes mentioned below.  
Initial Conc. Sample Final Conc. Volume for 1 
reaction(µl) 
2X Master mix 1X 12.5 
10uM Forward primer 0.5uM 1.25 
10uM Reverse primer 0.5uM 1.25 
 DNA 60 ng/ µl 3 
 GC enhancer  2.5 
 DEPC water  4.5 
Total reaction volume 25 
 
Holding Denaturation Annealing Extension Final extension 4 ̊C 
95 ̊C 95 ̊C 62 ̊C 72 ̊C 72 ̊C ∞ 
7 min 30 sec 30 sec 90 sec 7 min 
1 cycle 30 cycle 1 cycle 
 
The primer pairs used for the amplification and verification of the genes are given below. 
 
 
 
 
Table 3: PCR reaction composition 
Table 4: PCR programme 
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Primer Forward(5’-3’) Reverse(5’-3’) 
Human G-CSF specific 
primer 
 
SCF specific primer 
 
CAGTGCAGCATATGACC 
CCCCTGGGCCCT 
 
TAATGAGGATCCGGTGG 
AGGAGGTTCTGG 
 
GGGGATCCTCAGG 
GCTGGGCAAG 
 
TATTATCTCGAGTCA 
GGCTGCAACAGG 
Internal Primer GGAGAAGCTGGTGAGTG 
AGT 
 
TTCCCAGTTCTTCCATC 
TGC 
 
4.5 Agarose gel electrophoresis 
0.8 % agarose was prepared in 1X TAE buffer and ethidium bromide was added to it. The 
solution was poured to a casting tray with comb of appropriate size to set the gel. The 
casting tray was transferred to a gel tank filled with the electrophoresis buffer after the gel 
sets. DNA samples were mixed carefully with 6X DNA loading buffer and loaded onto 
the wells and the apparatus was runned. The DNA bands were visualized under 260 nm 
UV trans-illuminator. 
4.6 Restriction Digestion  
The restriction enzymes were purchased from New England Bio labs. Restriction 
digestion was performed for a time interval of 15 minutes at 37°C for the vector and the 
insert (hG-CSF). The RE digestion was carried out in a 25μL reaction with 5 units of 
restriction enzyme, 0.5μg of DNA and 1X CutSmart® Buffer each (Table 6). For all 
restriction digestion of pUC57-hGCSF and SCF 1 hour of incubation was followed to 
obtain all the restriction digested products. 
Component 
 
Concentration 
 
Volume used (μL) 
Nde I 
BamHI 
DNA 
CutSmart Buffer 
MB Grade Water 
5 Units 
5 Units 
0.5μg 
1X 
remaining 
0.25 
0.25 
10 
2.5 
12.5 
Total reaction volume 25 
Table 5: Primer Designed for GCSF expression 
Table 6: RE Digestion Reaction Composition 
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After restriction digestion the samples were run in a 0.8% Agarose gel (Low EEO) 
(Himedia MB002). The bands corresponding to the insert and vector size was excised 
using a sterile scalpel blade no.11 (Himedia LA769). The RE digested gene fragments 
were extracted from the gel using) and the OD values were taken to ascertain the purity 
and concentration of the gel purified nucleic acids. 
For all other restriction digestion carried out the above mentioned conditions were 
maintained. 
4.7 Gel elution of DNA  
PureLink Quick Gel Extraction Kit (Invitrogen) was used to elute the specific DNA 
fragemts from agarose gels. A small area of gel containing specific DNA fragment was 
excised and weighed. L3 Buffer was added to the gel containing DNA band in ratio of 3:1 
and heated in water bath.1 volume of isopropanol was added and the mixture was loaded 
on to an extraction column and centrifuged at maximum speed for 1 minute. 500 l of 
wash buffer was then added and centifuged at maximum speed for 1 minute. Washing 
step was repeated and 50 µl of the given elution buffer was then added and kept for 
incubation for around 10 minutes. It was then centifuged at maximum speed for 1 minute 
and the sample was stored at -20°C till further use. 
4.8 TOPO TA Cloning and Transformation 
The following table describes the TOPO® Cloning reaction.                   
Reagents required Volume(in µl) 
PCR product(fresh) 
Salt Solution 
TOPO® vector 
Total Volume 
4 
1 
1 
6 
 
2 µL of prepared TOPO reaction was added to chemically competent E. coli cells and 
mixed gently by tapping. The cell mixture was kept on ice for 15 minutes and then the 
cells were given heat-shock for 90 seconds at 42°C.The tubes were then transferred to ice 
and kept for 5 minutes. S.O.C. medium was added and the cell mixture was kept in shaker 
at 200 rpm at 37°C for 40 minutes.100 µL was spreaded from on a LB-Amp agar plate 
and incubated overnight at 37°C. 
Table 7:TOPO Cloning Reaction 
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 4.9 Colony PCR for screening transformants 
 A positive colony was carefully picked from an LB agar plate using tip of a pipette and 
transferred to a 0.5 ml centrifuge tube containing 50 µl of DEPC treated water. The 
solution was then vortexed. Then the tube was kept in a heat block at 99°C for 5 min. The 
tube was centrifuged at 12,000 × g for 1 minute. 5 µl of the supernatant was transferred to 
a 0.5 ml centrifuge tube and proceeded for PCR. 
 
Reagents Volume(in µl) 
2xMastermix 
Forward Primer(0.5µM) 
Reverse Primer(0.5µM) 
DNA (30 ng/µl) 
DEPC water 
Total Volume 
12.5 
1.25 
1.25 
5 
5 
25 
 
4.10 Recombinant Selection and Plasmid Isolation 
Colonies were inoculated in fresh LB broth and kept for overnight in shaker incubator. 
O.D. value of overnight grown culture was calculated and plasmid was isolated by both 
manual and miniprep method using Charge Switch Pro Plasmid Miniprep Kit. Isolated 
plasmid was runned in agarose gel and visualized under UV.  
4.11 Quantification of Isolated DNA 
The concentration of DNA was quantified spectrophotometrically in UV range. O.D. 
value of isolated DNA was measured at 230 nm,260 nm,280 nm and 320nm. The ratio of 
OD260 /OD280 was determined to check the purity of the sample. The concentration of 
DNA was calculated by using the following formula. 
DNA(ng//µl) =OD260 X50 X Dilution Factor 
4.12 Ligation of DNA fragments 
The DNA fragments digested with restriction enzyme so as to produce cohesive end were 
mixed with the digested vector. Vector (4.5Kb) was mixed with the insert (0.5Kb) in a 
molar ratio of 3:1.50 ng of vector and 16 ng of insert was used along with 0.5 U of T4 
DNA ligase(Invitogen) for carrying out ligation. The final volume of reaction was kept 20 
Table 8:Colony PCR 
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µl and the reaction mixture was incubated at 16 °C for 16 hours. The reaction was then 
heat inactivated at 65 °C for 20 minutes and digested with XhoI (killer cut) prior to 
transformation to chemically competent cells. 
For a three-way ligation all the components were maintained in the molar ratio of 1:1:1 
and all other reaction conditions were kept same. 
4.13 Preparation of E. coli competent cells 
100 µl of glycerol stock of E. coli cells was inoculated in 5 ml of LB broth and kept in 
shker for overnight incubation.500 µl of the overnight grown culture was used as 
inoculum for a 50 ml LB broth. When the cells reached to an OD of 0.4, they were 
transferred to pre chilled centrifuge tube under sterile conditions. Cells were harvested by 
centrifuging at 3000g for 15 minutes at 4°C.Supernatant was decanted and the pellet was 
dissolved in 100 mL of ice cold MgCl2.Cells were harvested at 2000g for 15 minutes at 
4°C. Supernatant was discarded and the pellet was dissolved in 200 mL of ice cold 
CaCl2.The cell suspension was incubated on ice for 20 minutes. Cells were then harvested 
by centrifuging at 2000g for 15 minutes at 4°C. Supernatant was discarded and the pellet 
was dissolved in 50 mL of ice cold 85 mM CaCl2, 15% glycerol. Cells were harvested at 
1000g for 15 minutes at 4°C.Transfer the suspension to the 50 mL conical tube. 
Supernatant was discarded and the pellet was dissolved in 5 mL of ice cold 85 mM CaCl2, 
15% glycerol.  50 µl aliquots were made in prechilled 1.5 mL centrifuge fuge tubes and 
snap freezed with liquid nitrogen. Frozen cells were stored -80°C freezer till further use. 
4.14 Transformation of E. coli cells 
100 µl of chemically competent cell was thawed on ice followed by addition of plasmid 
DNA. The cell mixture was kept on ice for 15 minutes. The cells were then given heat 
shock by keeping them in a preset water bath, at 42 ºC for 90 seconds. The cells were 
immediately transferred onto ice and incubated on ice for 5 minutes.SOC broth medium 
was added to the cell mixture kept on incubator shaker set at 37°C for 40 minutes.100 µl 
of cell mixture was plated on a LB ampicillin agar plate and plates were incubated at 
37°C for overnight. 
4.15 SDS-Polyacrylamide gel electrophoresis 
Glass plates, comb and spacers were cleaned and assembled. Separating(resolving) 
gel from the gap between the glass plates until filled to ¾th followed by with 
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immediate addition of isopropanol. The gel was left up to 30 minutes for 
polymerization. After solidification, stacking gel was poured and immediately a comb 
was inserted into the stacking gel solution, taking care to avoid trapping air bubbles. 
Now stacking gel was allowed to get polymerize. Now the glass plate was fixed in the 
electrophoresis apparatus and the gel tank was filled with 1X SDS Running Gel 
Buffer. Samples to be separated by SDS-PAGE were prepared as follows: 5 μl of 4 X 
SDS loading buffer was added to 15 μl of protein sample and the mixture was heated 
for 10 min at 70°C.Samples were loaded into different wells. The gel was runned until 
the dye front reached the bottom of the gel.  
4.16 Coomassie brilliant blue staining 
SDS-PAGE gels containing more than 200 ng protein concentration were visualised by 
Coomassie Brilliant Blue R 250 (CBB R 250) staining solution that comprises of 0.1% 
(w/v) CBB dissolved in 25% (v/v) of methanol and 10% (v/v) of acetic acid in water. De-
staining solution was prepared in the composition of water, methanol and acetic acid in 
the ratio of 50:40:10.  
4.17 Bioprocess and Protein Expression  
IPTG (1M) stock was prepared. BL21DE3-pET14b-hGCSF was cultured and induced 
with 1mM IPTG at 0.5 O.D. Hourly culture was harvested and O.D.(600nm) was 
recorded for both induced and uninduced culture. Specific growth rate for induced and 
uninduced culture was calculated. Graphs were plotted for growth curve and specific 
growth curve. After 0,4,6,8 hr 5ml of culture was withdrawn and centrifuged to obtain the 
cell pellet. Lysis buffer was prepared and 500µl of it was added to each cell pellet and the 
samples were then sonicated for 5minutes and kept at -20 ºC further use for running SDS 
PAGE. Similarly, IPTG concentration was varied from 0.2 to 1mM and protein 
expression was studied in presence of 1%,2% and 3% of ethanol. BL21DE3-pET14b-
hGCSF-SCF was cultured and induced with 1mM IPTG at 0.5 O.D. Hourly culture was 
harvested and O.D.(600nm) was recorded for both induced and uninduced culture. Protein 
expression was studied for different IPTG concentration and different period of induction. 
4.18 In silico Analysis of hG-CSF with mutations and fusion partner for 
improved bioactivity 
Genome compiler was used at all the simulation steps of the work. SWISS-MODEL was 
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used to model the native and mutant proteins based on the protein sequences. PyMOL 
was used to visualize the models designed. Hex 8.0.0 was used for docking of proteins 
with the receptor. ENCoM server was used to find the ddG values due to mutations and 
finally RAMPAGE was used for generating Ramachandran plots for the proteins. 
In silico analysis of GCSF fusion protein was carried out to measure the interaction of 
GCSF fusion protein with its respective receptor and to determine the hindrance of the 
fusion protein to GCSF. Protein sequence of GCSF, SCF, IL3, HLA, GCSF receptor and 
SCF receptor was retrieved from the NCBI (National Centre for Biotechnology 
Information) site. Sequence of fusion protein was made by combining the sequence of 
GCSF with its respective fusion partner via linker sequence. The protein sequence was 
then submitted in I-TASSER server to model the 3D structure of the GCSF fusion protein. 
Interaction and the binding affinity of the GCSF fusion proteins was analyzed using patch 
dock server. 
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Chapter 5 
Results and Discussion 
5.1 Isolation of human G-CSF from U-87 human glioblastoma cells 
 
U-87 human glioblastoma cells were cultured and maintained. Figure 10 shows the 
characteristic morphology of U-87 cells as seen under phase contrast microscope. 
 
 
Figure 10: Phase contrast microscopic images of U-87 human glioblastoma cells Magnification: 
10X. Scale bar: 100 µm 
 
RNA was isolated from U-87 cells and converted to cDNA as shown in figure 11 and 12. 
Bands were obtained for mRNA and smear was observed in cDNA gel. This cDNA was 
amplified with hG-CSF specific FP and RP primer and hG-CSF specific EEB primers as 
shown in figure 13. 
Band of 547 bp was obtained which inferred that hG-CSF was amplified using hG-CSF 
specific primers as inferred from the in silico analysis using genome compiler. Also a 
band of around 270 bp was obtained using hG-CSF specific internal EEB primers. hG-
CSF obtained in the gel was cut and gel purified and runned on agarose gel as shown in 
figure 14. Band size of around 547bp was obtained which confirms the presence of 
human G-CSF. 
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5.2 Isolation of human G-CSF from UCB 
 
Total RNA of Umbilical cord blood was isolated from the blood pellet as shown in 
figure15. RNA was converted to cDNA and amplified using hG-CSF specific primers as 
shown in figure 16 and 17 respectively. 
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Appropriate bands were obtained signifying the successful isolation of human GCSF. 
 
5.3 TOPO TA cloning of human G-CSF  
 
After successfully isolating human GCSF it was restriction digested and cloned in a 
TOPO vector. TOPO TA Cloning of GCSF was performed. Figure 18 illustrates the 
transformation result of the vector to the E. coli DH5α cells. The cells were then 
inoculated in LB broth and cultured. From grown culture plasmid was isolated as shown 
in figure 19. 
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Colonies were observed in the transformation plate. Band of around 4500 bp size was 
obtained which confirmed the presence of pTOPO-GCSF plasmid in the cells.  
 
5.4 Cloning of human G-CSF in pUC57 cloning vector 
 
The pUC57-GCSF plasmid was transformed to HiPuRA DH5α Competent cells. Colonies 
were observed in the transformation plate as shown in the figure 20. No colonies were 
observed in the negative transformation plate. 
After successful transformation, colonies were inoculated and grown overnight to proceed 
for isolation of plasmid (using Charge Switch Pro Mini Prep Kit). The isolated plasmids 
were runned in agarose gel as shown in figure 21. The bands of appropriate size were 
obtained. For further verification of successful transformation, PCR Amplification of the 
isolated plasmid with hG-CSF specific primers was carried out as shown in figure 22.        
 
Band of size of around 547 bp was observed in the lane loaded with PCR using hG-CSF 
specific primers. A faint band of around 2000bp was also observed suggesting that of the 
remaining plasmid DNA. However, no band was observed in the PCR reaction with non-
specific bands. Restriction digestion of pUC57-GCSF was performed with NdeI and and 
BamHI endonucleases. The agarose gel image of it is shown in the figure 23 
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Figure 23: Restriction digestion of pUC57-GCSF was performed with NdeI and and BamHI 
endonucleases. Lane 1:1kb Ladder,2: Restriction digested sample 
Restriction digestion of pUC57-GCSF resulted in four specific bands. The band with size 
of around 547bp was confirmed to be hG-CSF and thus was gel extracted for ligation with 
the expression vector. 
 
5.4 Isolation and restriction digestion of pET14b expression vector 
 
Expression vector pET14b was chosen for the expression of GCSF based on all the 
suitable features required for expression of the protein. The vector map is shown in figure 
24. 
 
Figure 24: Vector Map of pET14b 
L1    L2 
547 bp 
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Transformation of pET14b was carried out and the colonies obtained were grown 
overnight for isolation of plasmid. Specific band of size 4.6kb was obtained inferring that 
the isolated plasmids are pET14b as shown in figure 25. Restriction Digestion of pET14b 
with Nde I and Bam HI was performed and runned in agarose gel as shown in figure 26. 
The restriction digested sample gave a band of size was purified and proceeded for 
ligation with hG-CSF.                                                 
                                                                             
 
5.4 Ligation of human G-CSF with pET14b expression vector 
 
Restriction digested pET14b and G-CSF was purified using Pure Link Quick Gel 
Extraction kit(Invitrogen) as shown in the figure 27 and proceeded for ligation. 
 
                                                            
 
 
 
 
 
 
Figure 27: Insert and vector in agarose gel. Lane 1: Insert(hGCSF),2: Vector(pET14b) 
   L1   L2 
547 bp 
4.5kb 
bp 
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Ligation of cohesive ends of human G-CSF and pET14b was performed using T4DNA 
ligase(Invitrogen) at 16ºC for 16 hours. Heat inactivation and killer cut (using XhoI) was 
done to increase the specificity of ligation and transformation.  
 
5.5 Cloning of pET14b-hGCSF construct in DH5α  
 
Cloning of ligated pET14b-Hgcsf was performed in competent cells. The transformed 
plates are shown in the figure 28. 
 
Figure 28: Transformation plates with ligated vector and insert A, B, C: Ligation Plates 
Colonies were observed in the ligation plates along with no colony in the control plate. 
The colonies obtained in ligation plate were screened for presence of hG-CSF by PCR 
verification as shown in the figure 29. 
 
 
 
 
 
 
 
 
 
 
Figure 29: PCR verification of ligated colonies. Lane 1,3: PCR with hG-CSF specific 
primers.2:1kb Ladder 
The two colonies screened were found to contain human G-CSF as a band of size 547bp 
was obtained after PCR amplification. Also some nonspecific bands were observed which 
L1   L2    L3 
547 bp 
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were in multiples of 500bp suggesting there were chances of tandem incorporation of the 
gene. Also plasmid was isolated and verified by running in agarose gel.  
 
5.6 Cloning of pET14b-hGCSF construct in BL21DE3 
  
After successful verification of ligation of hG-CSF to pET14b, the ligated plasmid was 
transformed to BL21DE3 expression host. The transformation plates are shown in figure 
30. 
 
Figure 30: Transformation plates of pET14b-hGCSF construct in BL21DE3 A: Transformation 
plate B: Control Plate 
Colonies obtained were inoculated and cultured overnight. Plasmid was isolated (using 
Charge Switch Pro Mini Prep Kit) and quantified to have A260/280 ratio of 1.9 and DNA 
conc of 35 ng/µl. The isolated plasmid DNA was verified for the presence of human G-
CSF by PCR using human G-CSF specific primers. The result obtained is shown in the 
figure 31. All the plasmid gave PCR amplification for human GCSF. 
 
 
 
 
   
 
 
 
 
Figure 31: PCR verification of transformed colonies. Lane 1,2,3,4,6,7,8: PCR with GCSF specific 
primers.5:1kb Ladder 
L1    L2     L3    L4   L5    L6    L7   L8 
547 bp 
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5.7 In silico analysis of hG-CSF with mutations and fusion partner for 
improved bioactivity 
 
From the literature reviews it has been reported that N-terminal mutations have shown to 
increase the bioactivity of protein. With reference to this following five types of mutants 
were designed. 
 
 
 
 
 
 
SWISS-MODEL was used for the homology modeling of the native and the mutant 
proteins. The protein sequences were given as input for the modeler and it generated 
models of the protein PyMOL was used to visualize the modeled proteins by giving pdb 
files of the mutant proteins.            
 
Figure 32: Proteins modeled using SWISS-MODEL and visualized using PyMOL. A: Native 
protein B:M1 mutant C:M2 mutant D:M3 mutant E:M4 mutant F:M5 mutant 
Sites 2 4 5 6 18 
Wild T L G P C 
M1 A T Y R S 
M2 A T F R S 
M3 A T Y K S 
M4 G T Y R S 
M5 A Y Y R S 
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The native GCSF showed 100% similarity with template 1gnc.1. A which had a 
description of granulocyte colony stimulating factor. Mutants M1, M2, M3, M4 and M5 
showed 97.14,97.14,97.13,97.14 and 98.84% similarity respectively. Hex 8.0.0 was used 
to study the receptor-ligand interaction. GCSF receptor was docked with the native and 
all the five mutants.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: Receptor Protein interaction using Hex 8.0.0.A: Native protein B:M1 mutant 
C:M2mutant D:M3 mutant E:M4 mutantF:M5 mutant 
PROTEIN ETOTAL(KJ/mol) 
NATIVE -368.23 
M1 -362.07 
M2 -353.72 
M3 -368.6 
M4 -368.9 
M5 -372.52 
 
 
ETotal values were used to compare the binding interactions between the proteins.Mutant 
3,4 and 5 gave more ETOTAL value than the native protein inferring that all these 
mutants increased the binding affinity with M5 showing the highest affinity.M2 energy 
values were comparable to the native protein whereas M2 had a less binding affinity than 
the native one. Genome compiler and quick change site directed mutagenesis platform 
can be used to design the mutagenic primers.  
Table 9: ETOTAL values for the various interactions 
A                                             B                                               
C 
D                                             E                                                
F 
A                                                  B                                             C 
 
 
 
 
 
 
 D                                                   E                                          F 
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In silico analysis of GCSF fusion protein was carried out to check the interaction of 
GCSF fusion protein with respective receptors and with themselves. Tertiary structure of 
the GCSF fusion proteins were analyzed using I-TASSER to find the interaction of fusion 
proteins with its respective receptor. 
The three-dimensional structural of protein is important in providing insights to their 
molecular functions. The 3Dmodel of the GCSF/SCF fusion protein was generated using 
the I-TASSER online server along with their confidence score. Five models have 
generated by this server with C-Scores-3.41, 3.78, -4.05, -4.24, ¬-3.74 respectively.  
Among the 5models, model 1 has selected for further analysis as it contained the highest 
C-Score. 
 
Figure 34: Sequence and schematic model which has shown the construct of GCSF and SCF 
bound together by the SGGGGSGGGGSGGGGS linker. 
 
Figure 35: Graphical representation of secondary elements in chimeric GCSF-SCF protein 
 
 
Figure 36:  I-Tasser server was used to predict the 3D model of GCSF-SCF fusion protein 
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Ligand docking was performed using patch dock server. 3D Models of ligand 
(GCSF/SCF fusion protein) and receptors (GCSF receptor & SCF receptor) were 
uploaded in the software.  Default parameters were used for the interaction studies. 
Global energy value was used to select the efficient docking process. More efficient the 
docking more negatives the global energy value. 
 
Figure 37: Docking of GCSF-SCF with GCSFR using patchdock. To examine the protein ligand 
interactions, the models for ligand binding potency has predicted 
 
Figure 38: Docking of GCSF-SCF with GCSFR using patchdock. To examine the protein ligand 
interactions, the models for ligand binding potency has predicted. 
 
Global energy value obtained from the docking of GCSF-SCF fusion protein with 
GCSFR and SCFR receptors were -9.94 and -16.77 respectively.  Negative values of the 
docking process confirmed the higher affinity of the domains of fusion protein with its 
respective receptors. The result also confirmed that the fusion of SCF protein with GCSF 
protein do not affect the affinity of GCSF to its receptor. It was found that the SCF could 
be a good fusion partner of GCSF that enhance the bioactivity of GCSF. 
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5.8 Cloning of SCF in pUC57 cloning vector 
 
The pUC57-SCF plasmid was transformed to HiPuRA DH5α Competent cells. Colonies 
were observed in the transformation plate as shown in the figure 39. No colonies were 
observed in the negative transformation plate. 
 
Figure 39: Transformation plate of pUC57-SCF to DH5α Competent Cells A: Transformation 
plate B: Negative control plate 
 
After successful transformation, colonies were inoculated and grown overnight to proceed 
for isolation of plasmid. For verification of successful transformation, PCR Amplification 
of the isolated plasmid with SCF specific primers was carried out as shown in figure 40. 
Restriction Digestion of pET14b [Nde I & Xho I] was performed and the product was 
runned in agarose gel as shown in the figure 41. 
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Bands of appropriate size was obtained. Restriction Digestion of GCSF [Nde I and 
BamHI] and SCF [BamHI and XhoI] was further performed as shown in the figure 42. 
 
 
 
                   
 
 
 
 
 
Figure 42: Restriction Digestion of pET14b with Nde I & Xho I. Lane 1:1kb Ladder 2: Restriction 
digested GCSF product 3: Restriction digested SCF product 
 
5.9 Ligation of pET14b-hGCSF-SCF 
 
Three-Way Ligation of the restriction digested pET14b-GCSF-SCF was performed by 
adding all the samples in 1:1:1 ratio and was transformed to to DH5α Competent Cells. 
The transformation plates are shown in the figure 43. 
                            
Figure 43: Transformation plates with ligated vector and insert A: Ligation Plate B: Control Plate 
 
Colonies were obtained in the transformed plate whereas no colonies were obtained in 
control plate without plasmid. The colonies obtained were screened for the presence of 
GCSF and SCF by colony PCR. The colony PCR result is shown in figure 44. 
 
 
   L1     L2      L3 
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The colonies which gave positive result for SCF and GCSF were chosen for further 
analysis. Positive colonies were inoculated and grown overnight for plasmid isolation.  
The isolated plasmid was PCR verified for the presence of GCSF and SCF by using 
specific primers as shown in figure 45. Both the primers gave band of specific size with 
no nonspecific bands confirming the presence of both SCF and GCSF in the plasmid.  
 
5.10 Cloning of pET14b-hGCSF-SCF in BL21DE3 
 
The plasmid was then transformed to BL21DE3 expression host as shown in figure 46. 
 
Figure 46: Transformation of plasmid to BL21DE3 competent cells A: Transformation plate B: 
Negative control plate 
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5.11 Expression of human G-CSF 
 
1mM of IPTG was used to induce the overnight grown culture when the O.D. reached 0.5. 
O.D.600nm spectrophotometric readings of the induced and uninduced culture was 
recorded hourly. 0,4,6,8 and overnight grown induced and uninduced culture was 
harvested and proceeded for sonication and protein expression. 
 
 
Figure 47: Growth curve and specific growth rate curve of induced and uninduced culture. 
 
Further ethanol (%) was added to the culture to increase the biomass of the culture.The 
growth curve was anaysed for 0%,1%,2% and 3% ethanol addition and the graphs were 
plotted for the same as shown in figure 49. 
 
 
Figure 48: Growth curve at different ethanol concentration. 
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Both the growth curve and specific growth rate curve were higher for induced culture 
than uninduced culture.3% ethanol gave the highest growth upon analysis of effect of 
ethanol  
on culture conditions. The SDS-PAGE results for the same is shown in the figure 49. 
                                  
 
 
 
 
 
 
 
 
Figure 49: SDS-PAGE result of induced and uninduced culture of GCSF. Lane 1-4: Uninduced 
samples at 4,6,8 and overnight 5: Protein Ladder.6-9: Induced samples at 4,6,8 and overnight 
cultivation time. 
5.12 Expression of human G-CSF-SCF 
 
1mM of IPTG was used to induce the overnight grown culture containing fusion protein 
when the O.D. reached 0.5. O.D.600 nm spectrophotometric readings of the induced and 
uninduced culture was recorded hourly. 0,4,6,8 and overnight grown induced and 
uninduced culture was harvested and proceeded for sonication and protein expression. 
The SDS-PAGE result for the same is shown in figure 50. 
 
 
 
 
 
 
 
 
Figure 50: SDS-PAGE result of induced and uninduced culture of GCSF-SCF.Lane1: 
Uninduced,2: Induced (6 hr),3: Induced (8hr) 4: Ladder 5: Induced (12 hr) 
  1      2         3        4     5       6       7     8    9 
 18.9KDa 
1      2        3     4      5 
 40KDa 
Chapter 5                                                                                         Results and discussion 
 
42 
 
Protein band of 40 KDa was obtained as analyzed from the SDS-PAGE. No band was 
observed in the uninduced sample. However, for further confirmation western blotting 
with specific antibody is required. 
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Chapter 6 
Conclusion 
 
Total RNA was isolated from U-87 cell lines and umbilical cord blood, converted to 
cDNA and amplified with hG-CSF specific primers and hG-CSF specific EEB primers. 
The DNA obtained was then cloned into a TOPO vector and pUC57. Transformation of 
pUC57-hG-CSF was performed and the colonies obtained were verified for the presence 
of hG-CSF using PCR. The expression vector pET14b was chosen for the expression of 
the protein. After transforming and culturing the vector in E. coli cells it was restriction 
digested with Nde I and Bam HI for ligation with the digested hG-CSF. Ligated colonies 
were screened for the presence of human GCSF and then transformed to BL21DE3 
expression host and PCR verified for presence of hG-CSF. 
 Mutations in N-terminus of hG-CSF have shown to increase the bioactivity. Keeping this 
in mind five mutants were designed aiming to increase the bioactivity of the wild-type 
protein. All the mutants and the wild type were modelled and then their docking with the 
receptor was studied. Energy values were found to be more negative than the wild type in 
three of the five mutants. Genome compiler and Quick change primer design platform can 
be used to design the mutagenic primers to carry out the modifications. In order to check 
the interaction of fusion partner with GCSF protein in terms of receptor binding and 
folding in the fusion protein conformation, in silico analysis was carried out using I-
TASSER and patch dock sever respectively. It was found that the global energy values of 
docking of hG-CSF-SCF fusion protein with GCSFR and SCFR were -9.94 and -16.77 
respectively. This indicates the high affinity binding of the domains of hG-CSF-SCF 
fusion protein with its corresponding receptor. The visualization of docking result also 
suggested that the binding of one domain of the fusion protein in the binding site of 
receptor was not hindered by another domain. These findings suggested that the SCF 
could be a correct fusion partner of the GCSF protein. 
SCF was successfully cloned in pUC57 vector and a three-way ligation was carried out to 
fuse SCF with hG-CSF and pET14b. The colonies obtained was PCR verified to contain 
both hG-CSF and SCF and then transformed to DE3 competent cells. Growth profiles of 
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induced and uninduced culture were determined and protein expression was analysed. 
Induction for 8h gave the maximum protein expression as analysed by Image J software. 
IPTG concentration and ethanol (%) was also optimized for analysing increased protein 
expression. 
The IPTG concentration of 1mM along with 8hr of induction in the presence of 3% of 
ethanol was optimized for higher protein expression. Both hG-CSF and hG-CSF-SCF 
fusion partner was successfully expressed as analysed from SDS-PAGE. However, for 
further confirmation western blotting with hG-CSF specific antibody is required. 
Furthermore, other bioprocess parameters need to be optimized for increasing the protein 
expression along with purification and bioactivity analysis. 
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